ArticleLife (Basel, Switzerland)2025
Is a Bacteriophage Approach for Musculoskeletal Infection Management an Alternative to Conventional Therapy?
Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance is a global threat to public health. The growing resistance of bacteria to commonly used antibiotics necessitates the search for and development of alternative treatments. Bacteriophage (or phage) therapy fits this trend perfectly. Phages that selectively infect and kill bacteria might represent, in some cases, the last therapeutic option. This overview provides case examples and discusses the potential development of phage therapy, examining its ethical and legal considerations in the context of current clinical practices. Additionally, it explores the advantages of utilizing phage products in patients for whom existing therapeutic options are limited or unavailable. Further clinical studies are necessary to broaden the understanding of phages, their dosage, and a standardised delivery system. These efforts are essential to ensure that phage-based therapy is not viewed as experimentation but as a routine medical treatment. Bacterial viruses are unlikely to become a miracle cure or a panacea for infections, but they may find an important role in medicine. Full legalisation of this treatment could help solve the problem of multidrug-resistant infectious diseases on a global scale.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.